CE Marking of Digital Therapeutics: Classification and Regulatory Pathway
Digital therapeutics (DTx) are innovative digital medical devices designed to treat various pathologies and alleviate their symptoms. Unlike traditional medical devices, DTx achieve their therapeutic effects primarily through cognitive-behavioral modifications (like CBT) facilitated by digital platforms, rather than pharmacological or immunological means.
Why Digital Therapeutics Need CE Marking
DTx have medical purposes and, as such, fall under the MDR definition of medical devices. Whether it’s helping patients manage chronic diseases or treating mental health diseases’ symptoms, DTx must demonstrate compliance with MDR requirements through the CE marking process. This involves robust technical documentation, clinical evaluations, and quality management practices (implementation of a Quality Management System).
Classification of Digital Therapeutics (DTx) Under Rule 11 of the MDR
Rule 11 of the MDR 2017/745 determines the classification of Software as Medical Devices based on their intended use and potential risks. DTx are generally classified as Class I, IIa, or IIb, depending on the complexity of their functionalities and their impact on patient health. The regulatory pathway varies according to the classification. For Class I medical devices, self-certification is sufficient to obtain CE marking. For higher classes, manufacturers must certify their devices with a Notified Body. Therefore, it is crucial to justify the chosen classification in detail, relying not only on Rule 11 of the MDR 2017/745 but also on the MDCG 2019-11 guidance on the qualification and classification of software. This document provides additional guidelines for evaluating whether a software qualifies as a medical device and for rigorously determining its risk class.
Below are specific examples relevant to DTx:
- Class I (Low Risk): DTx tools offering basic functionalities without directly influencing medical decisions. Example: Software that monitors general health parameters (such as symptoms or physical condition) and provides a summary or personalized tracking, without clinical interpretation of the data, therapeutic recommendations, or alerts for healthcare professionals.
- Class IIa (Moderate Risk): DTx devices that provide information to assist in clinical decision-making, but where the consequences of failure are considered low. Example: An app that assists in diagnosing hearing dysfunction by interpreting auditory test data and proposes a personalized program to manage symptoms, while leaving the final decision to the healthcare professional.
- Class IIb (High Risk): DTx devices that provide critical information for diagnostic or therapeutic decision-making, where failure could result in serious harm to the patient.
Strategic Considerations for DTx Manufacturers
For DTx manufacturers, determining the appropriate classification is a critical step in balancing speed to market with regulatory compliance. While Class I devices with limited functionalities benefit from a simpler CE marking process, technical documentation remains essential to demonstrate compliance with the general safety and performance requirements. Conversely, for Class IIa or IIb devices, which are often associated with more complex therapies, manufacturers must prepare more comprehensive technical documentation and provide robust clinical validation data to meet stricter regulatory requirements.
Conclusion
The CE marking process is essential for digital therapeutics, ensuring they meet high standards of safety and effectiveness. By understanding the classification rules specific to DTx and aligning development strategies with MDR requirements, manufacturers can successfully bring their innovative solutions to the European market. Whether targeting basic self-management tools or advanced data-driven interventions, the classification of DTx under Rule 11 provides a clear regulatory framework to guide their development.
Discutons de vos projets
Ou
contactez nous à hello@sparta.care
